Table 1.1.
Consistently deregulated miRNAs in ovarian cancers.
| miRNAs | Alteration | Counterpart | Effect | Mechanism of Deregulation |
Targets | Associated References |
|---|---|---|---|---|---|---|
| Let- 7a/b/d/f |
Down- regulated |
HOSE, IOSE, ovary, fallopian tube from fimbriated end |
tumor suppressor |
promoter methylation, copy number variations |
KLK10, HMAG2 |
10,11,16,17,20,42,62,63 |
| miR-22 | HOSE | tumor suppressor |
ARRB1, CLIP2, EVI1,FRAT2, EDC3 |
8–10, 17, 20 | ||
| miR-31 | HOSE | tumor suppressor |
copy number variations |
E2F2, STK40, CEBPA |
9, 10 | |
| miR- 34a/b/c |
IOSE, ovary, fallopian tube from fimbriated end |
tumor suppressor |
promoter methylation, copy number variations and p53 mutation |
MET, CDK4 | 16, 17, 20, 23, 63 | |
| miR-125b | HOSE, IOSE, ovary, fallopian tube from fimbriated end |
putative tumor suppressor |
BCL3, VEGF, HIF-1α, HER3 |
10, 14, 16, 17, 41, 42, 62, 65 | ||
| miR-127- 3p |
HOSE, NOSE, ovary, serum |
related to drug-resistant |
imprinting, copy number variations, promoter methylation |
8, 10, 17, 20 | ||
| miR-152 | HOSE, IOSE, fallopian tube from fimbriated end |
putative tumor suppressor |
promoter methylation |
9, 10, 16, 20 | ||
| miR-155 | IOSE, blood, serum |
putative tumor suppressor |
20, 63 | |||
| miR- 181a-3p |
HOSE, ovary, blood |
copy number variations, promoter methylation |
10, 17 | |||
| miR-382 | HOSE | copy number variations, promoter methylation |
8–10 |